GUIDELINES FOR THERACON PRESENTATION:

1. All members of the group must participate in the presentation and discussion
2. The group must submit to the facilitator the following at the start of the presentation:
Printed slide presentation (6 slides/page)
Evaluation Rubric with names (for individual grading of presentation
3. All members must know the contents of the presentation
4. Presenters will be chosen by the facilitators
5. Questions will be reserved at the end of the presentation
ORDER OF PRESENTATION:
1. Summary of the Patients History
2. Include labs or procedures important in the triage of the patient ie 12 lead ECG
3. Salient Features
4. Diagnosis
5. General Principles / Goals of Therapy
6. Order Sheet DO NOT COPY THE ACTUAL ORDER SHEET UNLESS YOU AGREE WITH THE
CONTENTS TOTALLY!!!
7. Discussion
Indicate/ acknowledge sources of information
8. Summary
DISCUSSION:
Comparative PK/PD
Efficacy, Safety, Suitability, Cost comparison
Per Drug Class
Per Specific Class
Evidence-Based choice of drug - Journals, Published Guidelines, Meta Analysis
EFFICACY:
Set the target goals for an effective drug choice
Example:
Effective in stopping GI bleeding as evidenced by
a prospective randomized controlled study
or
Bactericidal for the following pathogens
Grade the efficacy (single or drug combination ):
++++ - meets all the set goals
+++ - meets 75% of the set goals
++ - meets 50% of the set goals
+ - meets 25% of the set goals
SAFETY:
Review the safety profile of the choices. List possible known side effects and adverse events
Grade the safety profile as follows:
++++ - has minor tolerable side effects, ceases when the drug is discontinued
+++ - significant, requires intervention but not requiring hospitalization
++ - side effect requires hospitalization
+ - potentially life threatening
0 - results in death
SUITABILITY:
Set the suitability criteria considering the patients profile, the disease and co-morbidities
Example:
1. Acute treatment, must be given parenterally
2. Disease being treated : Meningitis the drug must be able to cross the blood brain
barrier
3. Co-morbid illnesses: DM, hypertension, asthma
Grade the suitability
++++ - Has beneficial effect on identified co-morbid conditions; ideal for the patients profile and
disease state
+++ - Not known to adversely affect co-morbid conditions
++ - Meets 50% of the set goals
+ - Barely meets the criteria
0 - - Contraindicated because of the patients co-morbid conditions
COST:
Identify the cost per treatment course; if long-term treatment, cost/month
Grade the cost-effectiveness
++++ - least expensive of the choices
++ and +++ - in-betweens
+ - most expensive



CMM2011